v3.26.1
Segments of business and geographic areas
 3 Months Ended
Mar. 29, 2026
Segment Reporting [Abstract]  
Segments of business and geographic areas Segments of business and geographic areas
The Company is organized into two business segments: Innovative Medicine and MedTech.
The Company’s chief operating decision maker (CODM) is the Chief Executive Officer (Principal Executive Officer). For the Innovative Medicine and MedTech segments, the CODM uses segment income before tax to allocate resources (including employees, financial, and capital resources) for each segment predominantly in the annual forecasting process. The CODM considers planning-to-actual variances on a quarterly basis to assess performance and make decisions about allocating resources to the segments.
Sales by segment of business
 Fiscal First Quarter Ended
(Dollars in Millions)March 29,
2026		March 30,
2025		Percent
Change
INNOVATIVE MEDICINE
Oncology
U.S.
$3,6153,01320.0 %
International
3,3582,66426.0 
Worldwide
6,9735,67822.8 
DARZALEX
U.S.
2,2081,82920.7 
International
1,7561,40924.7 
Worldwide
3,9643,23722.5 
CARVYKTI
U.S.
43331836.2
International
16451*
Worldwide
59736962.1
TECVAYLI
U.S.
12710520.6 
International
744663.1
Worldwide
20215133.5 
TALVEY
U.S.
1016848.5 
International
5118*
Worldwide
1528676.7 
RYBREVANT/ LAZCLUZE
U.S.
17511355.1
International
8228*
Worldwide
25714182.7
ERLEADA
U.S.
34229217.3 
International
60747926.7 
Worldwide
94977123.1 
IMBRUVICA
U.S.
143235(39.1)
International
5174749.1 
Worldwide
660709(6.9)
 Fiscal First Quarter Ended
(Dollars in Millions)March 29,
2026		March 30,
2025		Percent
Change
OTHER ONCOLOGY(1)
U.S.
855458.8 
International
106160(33.9)
Worldwide
192214(10.6)
Immunology
U.S.
1,8552,196(15.5)
International
1,5241,5100.9 
Worldwide
3,3803,707(8.8)
TREMFYA
U.S.
1,04259973.9 
International
56635658.9 
Worldwide
1,60895668.3 
SIMPONI / SIMPONI ARIA
U.S.
269292(7.8)
International
3783663.0 
Worldwide
647659(1.7)
REMICADE
U.S.
269314(14.4)
U.S. Exports
181078.6 
International
136143(4.8)
Worldwide
422467(9.5)
STELARA
U.S.
220981(77.6)
International
435644(32.4)
Worldwide
6561,625(59.7)
OTHER IMMUNOLOGY
U.S.
381*
International
90*
Worldwide
461*
Neuroscience
U.S.
1,49496854.3 
International
6816790.3 
Worldwide
2,1751,64732.0 
SPRAVATO
U.S.
40627647.0 
International
614342.4 
Worldwide
46832046.4 
CAPLYTA(2)
U.S.
270—*
International
——— 
Worldwide
270—*
 Fiscal First Quarter Ended
(Dollars in Millions)March 29,
2026		March 30,
2025		Percent
Change
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
U.S.
75862521.2 
International
2802771.1 
Worldwide
1,03890315.0 
CONCERTA / methylphenidate
U.S.
2238(43.4)
International
1151104.3 
Worldwide
136148(8.0)
OTHER NEUROSCIENCE
U.S.
382832.6 
International
224248(9.7)
Worldwide
262277(5.4)
Pulmonary Hypertension (PH)
U.S.
83174411.7 
International
3042818.2 
Worldwide
1,1351,02510.7 
UPTRAVI
U.S.3853655.4 
International988614.3 
Worldwide4834517.1 
OPSUMIT/OPSYNVI
U.S.43336319.3 
International1721598.7 
Worldwide60652216.1 
OTHER PULMONARY HYPERTENSION
U.S.
1215(21.1)
International3437(8.3)
Worldwide 4652(12.1)
Infectious Diseases (ID)
U.S.
3423158.6 
International
54748712.2 
Worldwide
88980210.8 
EDURANT / rilpivirine
U.S.
78(13.1)
International
40235014.8 
Worldwide
40935814.1 
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
U.S.
3343059.5 
International
1099811.2 
Worldwide
44340310.0 
 Fiscal First Quarter Ended
(Dollars in Millions)March 29,
2026		March 30,
2025		Percent
Change
OTHER INFECTIOUS DISEASES
U.S.
12(56.9)
International
3639(8.3)
Worldwide
3741(10.4)
Cardiovascular / Metabolism / Other (CVM)
U.S.734855(14.2)
International142158(10.4)
Worldwide8761,013(13.6)
XARELTO
U.S.642690(7.0)
International——— 
Worldwide642690(7.0)
OTHER
U.S.91165(44.5)
International142158(10.4)
Worldwide233323(27.8)
Total PH, ID, CVM
U.S.1,9071,914(0.4)
International9939267.1 
Worldwide2,8992,8402.1 
TOTAL INNOVATIVE MEDICINE
 
 
U.S.8,8718,0929.6 
International6,5555,78113.4 
Worldwide15,42613,87311.2 
MEDTECH
Cardiovascular
U.S.1,3991,26110.9 
International97884216.1 
Worldwide2,3772,10313.0 
ELECTROPHYSIOLOGY
U.S.7366847.6 
International75363818.0 
Worldwide1,4891,32312.6 
ABIOMED
U.S.38933914.5 
International1008123.5 
Worldwide48842016.3 
SHOCKWAVE
U.S.24220617.8 
International635221.3 
Worldwide30525818.5 
 Fiscal First Quarter Ended
(Dollars in Millions)March 29,
2026		March 30,
2025		Percent
Change
OTHER CARDIOVASCULAR
U.S.32320.7 
International6272(13.4)
Worldwide94103(9.1)
Surgery
U.S.
1,046
1,002
4.4 
International
1,465
1,394
5.1 
Worldwide
2,511
2,396
4.8 
ADVANCED
U.S.4774574.2 
International6466164.9 
Worldwide1,1231,0734.6 
GENERAL
U.S.5695444.5 
International8197785.2 
Worldwide1,3881,3234.9 
Vision
U.S.5795662.4 
International78571310.1 
Worldwide1,3651,2796.7 
CONTACT LENSES / OTHER
U.S.4684523.7 
International5014677.2 
Worldwide9699195.5 
SURGICAL
U.S.111114(2.9)
International28524615.6 
Worldwide3963619.7 
Orthopaedics*
U.S.
1,435
1,384
3.7 
International
948
857
10.6 
Worldwide
2,383
2,241
6.3 
HIPS
U.S.
277
263
5.2 
International
159
146
8.9 
Worldwide
436
409
6.5 
KNEES
U.S.
239
231
3.3 
International
181
158
14.6 
Worldwide
420
389
7.9 
 Fiscal First Quarter Ended
(Dollars in Millions)March 29,
2026		March 30,
2025		Percent
Change
TRAUMA
U.S.
532
502
6.1 
International
301
270
11.4 
Worldwide
833
772
8.0 
SPINE, SPORTS & OTHER
U.S.
387
388
(0.1)
International
307
283
8.4 
Worldwide
694
671
3.5 
TOTAL MEDTECH  
U.S.4,4594,2135.9 
International4,1773,8079.7 
Worldwide8,6368,0207.7 
WORLDWIDE   
U.S.13,33012,3058.3 
International10,7329,58811.9 
Worldwide$24,06221,8939.9%
*    Percentage greater than 100% or not meaningful
(1) Includes the sales of ZYTIGA which were previously disclosed separately
(2) Acquired with Intra-Cellular Therapies on April 2, 2025

Adjustments to revenue recognized as a result of changes in estimates for the Company's most significant U.S. rebates and discounts liability balances for products shipped in previous periods were approximately 4.7% and 4.6% of U.S. Innovative Medicine revenue during the fiscal first quarter of 2026 and 2025, respectively.
*In October 2025, the Company announced its intention to separate its Orthopaedics business. The Company continues to explore multiple paths to effect the planned separation with a targeted completion within 18 to 24 months after the initial announcement.
Segment income before tax
 Fiscal First Quarter Ended
(Dollars in Millions)March 29,
2026		March 30,
2025
Innovative Medicine(1)
MedTech(2)
Total
Innovative Medicine(1)
MedTech(2)
Total
Sales to customers$15,4268,63613,8738,020
Cost of products sold4,3903,7014,0203,326
Selling, marketing and administrative2,9182,9062,2612,656
Research and development expense2,8137142,548677
Other segment items (3)
(12)76(166)(60)
Segment income before tax$5,3171,2396,5565,2101,4216,631
(Income)/Expense not allocated to segments (4)
566(7,000)
Earnings before provision for taxes on income$5,990$13,631
(1) Innovative Medicine includes:
•Intangible amortization expense of $0.8 billion and $0.6 billion in the fiscal first quarters of 2026 and 2025, respectively.
(2)    MedTech includes:
•Intangible amortization expense of $0.5 billion in both the fiscal first quarters of 2026 and 2025.
•Orthopaedics Separation related charge of $0.1 billion in the fiscal first quarter of 2026.
•Acquisition and integration related expense of $0.1 billion in the fiscal first quarter of 2025, primarily related to Shockwave.
(3)    Other segment items for each reportable segment include other income and expense (gains and losses on divestitures and gains and losses on sale of assets), restructuring activities and impairment charges related to in-process research and development
(4) Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal first quarter of 2026 includes charges for talc matters of $0.3 billion. The fiscal first quarter of 2025 includes approximately $7.0 billion related to the talc reserve reversal.
Identifiable Assets
(Dollars in Millions)March 29, 2026December 28, 2025
Innovative Medicine$78,118
78,057
MedTech86,17986,482
Total
164,297
164,539
General corporate (1)
36,59734,671
Worldwide total$200,894199,210
(1)General corporate includes cash, cash equivalents, marketable securities and other corporate assets.
Additions to Property,
Plant & Equipment		Depreciation and
Amortization
Fiscal Three Months Ended
(Dollars in Millions)March 29, 2026March 30, 2025March 29, 2026March 30, 2025
Innovative Medicine$508276$1,036884
MedTech509480903836
Segments total1,0177561,9391,720
General corporate32396552
Worldwide total$1,049795$2,0041,772
Sales by geographic area
 Fiscal First Quarter Ended
(Dollars in Millions)March 29, 2026March 30, 2025Percent
Change
United States$13,33012,3058.3%
Europe5,8485,11014.5 
Western Hemisphere, excluding U.S.1,2931,16710.8 
Asia-Pacific, Africa3,5913,3118.5 
Total$24,06221,8939.9%